A 2-part webinar for scientists interested in novel drug delivery methods for basic research, drug discovery and development. Learn about novel infusion technologies and how challenges in physiological monitoring and drug delivery are being overcome by implantable and programmable devices.

Christian Schnell, Lab Head of in-vivo Pharmacology and Oncology Research at Novartis in Basel, Switzerland presents data from multiple species that show how differences in blood pressure, heart rate and acute stress impact drug activity and how dosing a pre-trained animal can influence hemodynamic parameters.

Additional References:

Discovering and Developing Molecules with Optimal Drug-Like Properties 
Editors: Allen C Templeton, Stephen R. Byrn, Roy J Haskell, Thomas E. Prisinzano
ISBN: 978-1-4939-1398-5 (Print) 978-1-4939-1399-2 (Online) 27 Sep 2014  
Discovery Formulations: Approaches and Practices in Early Preclinical Development
Shobha N. Bhattachar, David M. Bender, Stephanie A. Sweetana, James A. Wesley
Discovering and Developing Molecules with Optimal Drug-Like Properties
AAPS Advances in the Pharmaceutical Sciences Series Volume 15, 2015, pp 49-94 Chapter 2, 27 Sep 2014Enabling Discovery Through Leveraging and Miniaturizing Pharmaceutical Principles and Processes
Roy J. Haskell, Kimberly A. Foster, Ching Kim Tye, Michael Morgen
Discovering and Developing Molecules with Optimal Drug-Like Properties
AAPS Advances in the Pharmaceutical Sciences Series Volume 15, 2015, pp 95-140 Chapter 3, 27 Sep 2014Implementation of pharmacokinetic and pharmacodynamic strategies in early research phases of drug discovery and development at Novartis Institute of Biomedical Research
Tove Tuntland, Brian Ethell, Takatoshi Kosaka, Francesca Blasco, Richard Xu Zang, Monish Jain, Ty Gould, Keith Hoffmaster.
Front. Pharmacol., 28 July 2014

Optimising in vivo pharmacology studies—Practical PKPD considerations
Johan Gabrielsson, A. Richard Green, Piet H. Van der Graaf
Journal of Pharmagological and Toxicological Methods, Volume 61, Issue 2, March-April 2010, pp 146-156.

Syracuse University Magazine Article on Dr Robert Doyle’s Research

Click to watch the webinar recording. To view the presentation full screen simply click the square icon located in the bottom-right corner of the video-viewer.


To retrieve a PDF copy of the presentation, click on the link below the slide player. From this page, click on the “Download” link to retrieve the file.


Associate Director Oncology NIBR
Novartis in Basel

Christian joined NOVARTIS (previously CIBA-GEIGY) in 1980, first in Cardiovascular Research followed by Oncology Research since 1994. He was actively involved in the profiling of several compounds that entered the clinical development and reached the market like DIOVAN®, RASILEZ®, GLEEVEC®, ZOMETA®, AFFINITOR® and PIQRAY ®. Christian was one of the first to adapt fully implantable telemetry devices for blood pressure and ECG recordings in conscious unrestrained marmosets (1993), for intraocular pressure measurements in the vitreous of conscious unrestrained rabbits (1996), and for the measurement of tumour interstitial pressure in conscious unrestrained rats and mice (2003). Currently, he is the 3R’s representative for Oncology Basel at Novartis.

Production Partner

iPRECIO Micro Infusion Pumps

iPRECIO offers innovative drug infusion technology for laboratory animals. The ability to program the device to start, stop and deliver different doses at different time points or just deliver one continuous dose makes iPRECIO ideally suited to the drug discovery and basic research process. iPRECIO micro-infusion pumps are manufactured and supported by Primetech Corporation.

Additional Content From iPRECIO Micro Infusion Pumps

Related Content